Macrogenics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 339

Market Cap: $215.1M

Website

Introduction: MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E...

Clinical Trials

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Phase 2

Withdrawn

Conditions: Squamous Cell Carcinoma of Head and Neck
Head and Neck Cancer

Interventions: Biological: enoblituzumab
Biological: MGA012
Biological: MGD013

First Posted Date: 2019-10-16

Last Posted Date: 2022-02-08

Lead Sponsor: MacroGenics

Registration Number: NCT04129320

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Phase 2

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer
HER2-positive Gastric Cancer

Interventions: Biological: margetuximab
Biological: Trastuzumab
Biological: Retifanlimab
Biological: Tebotelimab
Other: Chemotherapy

First Posted Date: 2019-09-09

Last Posted Date: 2024-05-16

Lead Sponsor: MacroGenics

Target Recruit Count: 82

Registration Number: NCT04082364

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States

and more 70 locations

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Phase 1

Active, not recruiting

Conditions: Squamous Cell Non Small Cell Lung Cancer
Cutaneous Melanoma
Solid Tumor, Adult
Prostate Cancer Metastatic
Colorectal Cancer
Advanced Cancer

Interventions: Biological: Lorigerlimab

First Posted Date: 2018-12-03

Last Posted Date: 2024-05-09

Lead Sponsor: MacroGenics

Target Recruit Count: 162

Registration Number: NCT03761017

Locations: 🇺🇸
UPMC Pinnacle - Ortenzio Cancer Center (OCC), Mechanicsburg, Pennsylvania, United States
🇺🇦
Sumy Clinical Oncological Hospital, Sumy, Ukraine
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 33 locations

MGC018 With or Without MGA012 in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Castrate Resistant Prostate Cancer
Melanoma
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Advanced Solid Tumor, Adult

Interventions: Biological: vobramitamab duocarmazine

First Posted Date: 2018-11-02

Last Posted Date: 2024-04-23

Lead Sponsor: MacroGenics

Target Recruit Count: 143

Registration Number: NCT03729596

Locations: 🇺🇸
The Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Virginia Cancer Specialist, Fairfax, Virginia, United States
🇺🇸
UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States

and more 18 locations

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

Phase 1

Completed

Conditions: HIV-1-infection

Interventions: Biological: MGD014

First Posted Date: 2018-06-27

Last Posted Date: 2022-09-02

Lead Sponsor: MacroGenics

Target Recruit Count: 21

Registration Number: NCT03570918

Locations: 🇺🇸
University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Biological: MGD007 + MGA012

First Posted Date: 2018-05-22

Last Posted Date: 2022-02-08

Lead Sponsor: MacroGenics

Target Recruit Count: 38

Registration Number: NCT03531632

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

and more 3 locations

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: obrindatamab
Biological: retifanlimab

First Posted Date: 2018-01-23

Last Posted Date: 2022-05-19

Lead Sponsor: MacroGenics

Target Recruit Count: 25

Registration Number: NCT03406949

Locations: 🇺🇸
START (South Texas Accelerated Research Therapeutics) - Midwest, Grand Rapids, Michigan, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 7 locations

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

First Posted Date: 2017-07-17

Last Posted Date: 2023-12-21

Lead Sponsor: MacroGenics

Target Recruit Count: 277

Registration Number: NCT03219268

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
🇧🇬
"Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda" EAD, Sofia, Sofia, Bulgaria
🇵🇱
Med-Polonia Sp. z o.o., Poznań, Poland

and more 36 locations

Margetuximab Expanded Access Program

Conditions: HER2-positive Breast Cancer
HER2-positive Carcinoma

First Posted Date: 2017-04-28

Last Posted Date: 2022-02-22

Lead Sponsor: MacroGenics

Registration Number: NCT03133988

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Rhabdomyosarcoma
Osteosarcoma
Ewing Sarcoma
Wilms Tumor
Desmoplastic Small Round Cell Tumor

Interventions: Drug: Enoblituzumab

First Posted Date: 2016-12-06

Last Posted Date: 2022-02-08

Lead Sponsor: MacroGenics

Target Recruit Count: 25

Registration Number: NCT02982941

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸
National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy